Media coverage about CAS Medical Systems (NASDAQ:CASM) has been trending somewhat negative recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CAS Medical Systems earned a media sentiment score of -0.04 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 46.6072086099101 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Europe Neurological Monitoring Devices Market 2017: Key Players, Development and Opportunities by Forecast to 2021 (emailwire.com)
- Europe Neurological Monitoring Devices Market 2017: Key Players,Development and Opportunities (reports.pr-inside.com)
- Global Intracranial Pressure Monitors Market is Determined to Cross US$ 1.50 Billion By 2023 (medgadget.com)
- Global Intracranial Pressure Monitors Market Expected To Be Worth US$ 1.60 Billion By 2023 (openpr.com)
- Intracranial pressure monitoring Business Patterns That Will Drive Accomplishment In 2024 (medgadget.com)
CAS Medical Systems (NASDAQ:CASM) traded up 5.39% on Tuesday, hitting $0.88. The stock had a trading volume of 189 shares. CAS Medical Systems has a 52-week low of $0.80 and a 52-week high of $1.94. The stock’s 50-day moving average is $0.90 and its 200-day moving average is $1.07. The company’s market cap is $24.05 million.
CAS Medical Systems (NASDAQ:CASM) last released its quarterly earnings data on Tuesday, August 8th. The medical technology company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $5.41 million. Analysts expect that CAS Medical Systems will post ($0.27) earnings per share for the current year.
Separately, ValuEngine lowered CAS Medical Systems from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
COPYRIGHT VIOLATION NOTICE: “Somewhat Negative Press Coverage Somewhat Unlikely to Impact CAS Medical Systems (CASM) Stock Price” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/cas-medical-systems-casm-earning-somewhat-negative-media-coverage-study-shows/1698848.html.
CAS Medical Systems Company Profile
CAS Medical Systems, Inc is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It operates through Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories.
Receive News & Ratings for CAS Medical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAS Medical Systems Inc. and related companies with our FREE daily email newsletter.